HIF2A expression has been associated with aggressive disease phenotype, metastasis and resistance to therapy in several solid tumors, such as neuroblastoma [20], non-small cell lung cancer [21], and breast cancer [22]. Here, EPAS1 is linked to non-small cell lung carcinoma.